Complete Summary

TITLE

Diagnosis and outpatient management of asthma: percentage of adults with persistent asthma who are on inhaled corticosteroids medication.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Diagnosis and outpatient management of asthma. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2005 Mar. 49 p. [31 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the <u>Measure Validity</u> page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of adults with persistent asthma who are on inhaled corticosteroids medication.

RATIONALE

The priority aim addressed by this measure is to promote long-term control of persistent asthma through the use of inhaled corticosteroid drug therapy.

PRIMARY CLINICAL COMPONENT

Persistent asthma; inhaled corticosteroids medication (beclomethasone HFA, triamcinolone, fluticasone, flunisolide, budesonide, fluticasone propionatel/salmeterol dry powder inhaler [DPI])

DENOMINATOR DESCRIPTION

Number of adults, age 18 through 39, with persistent asthma* who were continuously enrolled for 6 months

*Adults with a diagnosis code of 493.00, 493.01, 493.10, 493.11, 493.90, or 493.91

NUMERATOR DESCRIPTION

Number of adults in the denominator who have one or more prescriptions filled for inhaled corticosteroids medications:

- beclomethasone HFA
- triamcinolone
- fluticasone
- flunisolide
- budesonide
- fluticasone propionatel/salmeterol DPI

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

 A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

NATIONAL GUIDELINE CLEARINGHOUSE LINK

<u>Diagnosis and outpatient management of asthma.</u>

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

TARGET POPULATION AGE

Adults age 18 through 39 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness

Data Collection for the Measure

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

Adults age 18 through 39 with persistent asthma, continuously enrolled for 6 months

Data may be collected electronically using the pharmacy database, the claims/encounter database or the enrollment database.

It is suggested that data are collected quarterly.

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

Number of adults, age 18 through 39, with persistent asthma* who were continuously enrolled for 6 months

*Adults with a diagnosis code of 493.00, 493.01, 493.10, 493.11, 493.90, or 493.91

Exclusions Unspecified

DENOMINATOR (INDEX) EVENT

Clinical Condition

DENOMINATOR TIME WINDOW

Time window is a fixed period of time

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Number of adults in the denominator who have one or more prescriptions filled for inhaled corticosteroids medications:

- beclomethasone HFA
- triamcinolone
- fluticasone
- flunisolide
- budesonide
- fluticasone propionatel/salmeterol DPI

Exclusions

Unspecified

NUMERATOR TIME WINDOW

Fixed time period

DATA SOURCE

Administrative data Pharmacy data

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

Percentage of adults with persistent asthma who are on inhaled corticosteroids medication.

MEASURE COLLECTION

Diagnosis and Outpatient Management of Asthma Measures

DEVELOPER

Institute for Clinical Systems Improvement

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2005 Mar

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Diagnosis and outpatient management of asthma. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2005 Mar. 49 p. [31 references]

MEASURE AVAILABILITY

The individual measure, "Percentage of adults with persistent asthma who are on inhaled corticosteroids medication," is published in "Health Care Guideline: Diagnosis and Outpatient Management of Asthma." This document is available from the Institute for Clinical Systems Improvement (ICSI) Web site.

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

NQMC STATUS

This NQMC summary was completed by ECRI on June 3, 2005.

COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

© 2006 National Quality Measures Clearinghouse

Date Modified: 8/21/2006

FIRSTGOV

